Imperial College London
Portrait Picture

Professor Sarah Fidler BSc. MBBS. FRCP. PhD

Faculty of Medicine, Department of Infectious Disease

Professor of HIV and Communicable Diseases
 
 
 
//

Contact

 

+44 (0)20 7594 6230s.fidler

 
 
//

Location

 

clinical trial centre Winston Churchill wingMedical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@inproceedings{Nkhoma:2020:10.1111/hiv.12860,
author = {Nkhoma, K and Lwanga, J and Ryan, F and Lee, M and Bristowe, K and Harding, R and Fidler, S and Frater, J and Fox, J},
doi = {10.1111/hiv.12860},
pages = {23--24},
publisher = {Wiley},
title = {Prospective interruption of therapy towards a cure for HIV (PITCH): experiences of patients on treatment interruption (TI)},
url = {http://dx.doi.org/10.1111/hiv.12860},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - CPAPER
AB  - Background: Increasingly cure trials require a treatment interruption (TI) in order to evaluate whether an intervention has worked. In order to ensure that future TI trials are designed sensitively with participants at the heart of the process, we carried out qualitative interviews with individuals taking part in the PITCH TI study.Method: We recruited participants with primary HIV infection, who commenced ART within three months of diagnosis, have been on ART for at least two years with HIV1 DNA levels <3.25 log copies/million CD4 T cells, CD4 count >500 or CD4:8 ratio> 1, with suppressed plasma VL < 50 copies HIV RNA/ml.Upon ART cessation, for the first 12 weeks participants were required to undergo point ofcare quantitative GeneXpert viral load testing on a twice per week basis, with additional visits if desired. Indepth qualitative facetoface interviews were conducted two weeks before, at least two weeks during and two weeks after TI. The interviews aimed to explore views and experiences about TI.Results: Five out of six participants participated: n=3 were interviewed before TI, n=5 were interviewed during TI and n=4 were interviewed after TI.Seven themes were identified: 1) Motivation to participate: all participants reported participation in TI was to help others in future. 2) Benefits of TI: Stopped experiencing ART side effects and being off treatment saved NHS money. 3) Challenges of TI: frequent appointments with NHS for blood test. 4) Risks associated with TI: passing on HIV if detectable. Participants used prevention tools (PrEP/condoms). 5) Vicious cycle of worry: anxious/worried their viral load was going up and that they might transmit HIV. 6) Being undetectable: participants knew that undetectable=untransmittable. 7) Treatment rotation: TI is not a cure butswapping treatment with the partner who has to take PrEP.Conclusion: Participants found that taking a TI as part of a cure trial to be a positive experience and valued the break f
AU  - Nkhoma,K
AU  - Lwanga,J
AU  - Ryan,F
AU  - Lee,M
AU  - Bristowe,K
AU  - Harding,R
AU  - Fidler,S
AU  - Frater,J
AU  - Fox,J
DO  - 10.1111/hiv.12860
EP  - 24
PB  - Wiley
PY  - 2020///
SN  - 1464-2662
SP  - 23
TI  - Prospective interruption of therapy towards a cure for HIV (PITCH): experiences of patients on treatment interruption (TI)
UR  - http://dx.doi.org/10.1111/hiv.12860
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000588553700053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://onlinelibrary.wiley.com/doi/full/10.1111/hiv.12860
UR  - http://hdl.handle.net/10044/1/88265
ER  -
Download